CROSSJECT Secures €5.7 Million in Capital Increase for Growth

CROSSJECT Successfully Raises €5.7 Million in Capital Increase

CROSSJECT, a rising name in specialty pharmaceuticals, has successfully completed a capital increase totaling more than €5.7 million. This achievement comes after a full exercise of the extension clause, indicating strong investor confidence and demand in the company’s growth potential.

Exciting Details of the Capital Increase

The capital increase witnessed a remarkable total demand of over €9.2 million, translating to an oversubscription rate reaching 1.84 times. Notably, this transaction was significantly supported by Gemmes Venture along with investments from the new investor, Vatel Capital, highlighting the collaborative effort in fostering investor trust and commitment to the company's future.

Context of Financial Needs

The funds raised will play a critical role in completing the final phases of registration and initial production of ZEPIZURE®, an emergency treatment designed for managing epileptic seizures. Currently advancing through late-stage clinical and regulatory development, ZEPIZURE® utilizes the award-winning ZENEO® needle-free auto-injector technology, making it accessible and easy to administer in emergency situations.

Chairman's Insights

Patrick Alexandre, Chairman of the Management Board, expressed gratitude towards the shareholders for their enthusiastic participation, which surpassed initial expectations. He emphasized confidence in entering the final steps of ZEPIZURE®’s development journey, especially with the financial foundation now secured for pre-commercialization efforts.

Objectives and Strategic Moves

Looking ahead, CROSSJECT is focused on preparing for the Emergency Use Authorization (EUA) submission to the FDA, with a well-structured timeline for the validation batch productions that are set to proceed. Collaboration with the Biomedical Advanced Research and Development Authority (BARDA) aligns with the company's strategic interests in ensuring national preparedness against chemical threats through the CHEMPACK program.

Utilization of Funds

In terms of allocation, approximately 60% of the net proceeds from the offering will directly support the final development phases of ZEPIZURE® and its initial production stages. The remaining 40% is earmarked for financing research and development projects related to other promising products, including ZENEO® Adrenaline and ZENEO® Hydrocortisone, and to manage overall operational costs.

Evaluating Future Financial Flexibility

With the capital secured, CROSSJECT anticipates that its current net working capital will be adequate to meet obligations through the end of 2025, assuming timely payments from its U.S. partner following initial deliveries. The company remains vigilant, evaluating both dilutive and non-dilutive financing options to ensure robust cash flow management.

Upcoming SEC Filings

A major highlight will be the expected filing for the second NDA in the second quarter of 2026, showcasing CROSSJECT's commitment to diversifying its product offerings and enhancing its pipeline with innovative solutions. The funds bolster CROSSJECT's preparedness to meet its ambitious objectives effectively.

Company's Capital Structure Post-Increase

Following the completion of the capital increase, CROSSJECT's share capital will amount to approximately €5,032,022.40, representing a significant step toward solidifying its market presence and capabilities within the pharmaceutical sector.

Conclusion and Future Prospects

CROSSJECT is embarking on a promising journey to enhance its position in the pharmaceutical landscape with the successful capital raise. As the company pushes forward, it remains dedicated to innovation and addressing critical healthcare needs through its unique product line, notably the groundbreaking ZEPIZURE® treatment.

Frequently Asked Questions

What is the purpose of the €5.7 million capital increase?

The funds are aimed at supporting the final registration phases of ZEPIZURE® and the start-up of initial production stages, enhancing operational capabilities.

How did the market respond to the capital increase?

The market showcased strong demand, with total subscriptions exceeding €9.2 million, leading to an oversubscription rate of 1.84 times.

What percentage of the funds will be allocated to ZEPIZURE®?

Approximately 60% of the proceeds will be directed towards the final development phases of ZEPIZURE® and related inventory buildup.

Who supported the capital increase?

The transaction received backing from Gemmes Venture and new investor Vatel Capital, among others, demonstrating investor confidence in CROSSJECT’s strategy.

What are CROSSJECT’s future plans with its other product candidates?

The company intends to advance development projects for ZENEO® Adrenaline and ZENEO® Hydrocortisone while maintaining its focus on ZEPIZURE®.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.